Neuren Pharmaceuticals

February 24, 2020

First fragile X test is approved, and Zynerba could benefit

The fragile X pipeline is strewn with failures, and crunch time is approaching for Zynerba’s cannabinoid.

September 06, 2019

Upcoming events – Obseva's first fibroid foray and Newron's test in Retts

Obseva awaits data that could make linzagolix third to market, while Newron looks for a starring role in Retts.

August 07, 2018

Neuren pays the price for sellside froth

The Australian group has found a partner for its lead asset at last, so why is the stock down?

October 10, 2014

Upcoming events: Rett data for Neuren while NPS awaits Natpara approval

May 01, 2014

Novartis exit leaves Fragile X pipeline in an even more frail state

April 18, 2012

Therapeutic Focus – research into autism gains momentum

June 01, 2010

Therapeutic focus - Innovation lags in stroke treatment